Daniel Armstrong

Dr. Armstrong's primary focus is on mechanisms of neurocognitive impairment in children treated for ALL and CNS tumors using chemotherapy and/or radiation therapy and on approaches to prevent or lessen the severity of impairment following successful treatment. He also conducts interdisciplinary investigations of relationships between neuroimaging findings of CNS structural changes, biochemical pathways, and functional outcomes. Additionally, a recent focus concerns the potential linkage between high dose methotrexate in treatment of ALL and late onset of autism spectrum symptoms.